Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 27,153 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Activity Clear all
Suspended Phase 1 Interventional

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

NCT05400122
View directory record Official record
Conditions
Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma, Gastric Cancer, Esophageal Cancer, Esophagus Cancer, Gastric Cancer, Metastatic, Unresectable Esophageal Cancer, Metastatic Esophageal Cancer
Interventions
Vactosertib, Fludarabine Phosphate, Cyclophosphamide, IL-2, Natural Killer Cells
Drug
Lead sponsor
David Wald
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 29, 2026, 2:30 PM EDT
Not listed Not applicable Interventional

Unobtrusive Sensing of Medication Intake ("USE-MI")

NCT03571022
View directory record Official record
Conditions
Medication Adherence
Interventions
USE-MI System
Behavioral
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 29, 2026, 2:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Testing a Wearable Monitor for Fetal Heart Rate Estimation, Fetal Movement and Uterine Activity Detection

NCT04450251
View directory record Official record
Conditions
Pregnancy
Interventions
Data Collection
Other
Lead sponsor
Owlet Baby Care, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Lehi, Utah
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Not applicable Interventional Results available

Treating Primary Progressive Aphasia (PPA) Using tDCS

NCT04566731
View directory record Official record
Conditions
Primary Progressive Aphasia
Interventions
Transcranial Direct Current Stimulation (tDCS), Sham tDCS, Modified Contraint-Induced Language Therapy (mCILT)
Device · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 29, 2026, 2:30 PM EDT
Completed No phase listed Observational Results available

Monitoring Movement and Health Study

NCT03084302
View directory record Official record
Conditions
Pregnancy Related, Obesity, Hypertension
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
120 participants
Timeline
2017 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 29, 2026, 2:30 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

NCT07321873
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
JNJ-88545223, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
18
States / cities
Searcy, Arkansas • Huntington Beach, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 29, 2026, 2:30 PM EDT
Enrolling by invitation Not applicable Interventional

Adolescent Surgery Roadmap Feasibility and Acceptability Study

NCT06991673
View directory record Official record
Conditions
Pediatric Surgical Procedures
Interventions
Behavioral Treatment
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
12 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Ann Arbor, Michigan • Brighton, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.

NCT00651469
View directory record Official record
Conditions
Acne Vulgaris
Interventions
YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
14 Years to 45 Years · Female only
Enrollment
534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
27
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Not applicable Interventional Results available

Evaluation of Robotic Arm Rehabilitation in Stroke Patients

NCT00333983
View directory record Official record
Conditions
Stroke
Interventions
Robotic Upper Extremity Neurorehabilitation, Traditional Upper Extremity Exercise Group
Device · Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2014 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Not applicable Interventional Results available

Alzheimer's Prevention Through Exercise

NCT02000583
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aerobic Exercise, Standard of Care
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103)

NCT05567354
View directory record Official record
Conditions
Recreational Drug Use
Interventions
PF614, Oxycodone, Placebo
Drug · Other
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Not applicable Interventional

EMPOWER AUD Pivotal Trial

NCT05948605
View directory record Official record
Conditions
Alcoholism, Alcohol Abuse, Alcohol Use Disorder
Interventions
Empower Neuromodulation System
Device
Lead sponsor
Theranova, L.L.C.
Industry
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
San Francisco, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Evaluation of a School Climate Videogame Intervention

NCT04025294
View directory record Official record
Conditions
Cognitive Reappraisal, Self Efficacy
Interventions
videogame, School Climate Assessment Survey
Device · Behavioral
Lead sponsor
Yale University
Other
Eligibility
14 Years to 19 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Not applicable Interventional

Reducing the Weight of Overweight Schizophrenia Patients

NCT00158366
View directory record Official record
Conditions
Schizophrenia, Obesity
Interventions
Behavioral training, Social skills training, Behavioral training booster sessions
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
14 Years to 60 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Wisconsin Center for the Neuroscience and Psychophysiology of Meditation

NCT02157766
View directory record Official record
Conditions
Mindfulness, Compassion, Meditation, Mental Health, Asthma
Interventions
Intensive Meditation Practice, Mindfulness Based Stress Reduction, Health Enhancement Program
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
457 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
4
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Micronutrients for Attention-Deficit Hyperactivity Disorder in Youth (MADDY) Study

NCT03252522
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants, Placebo
Combination Product · Dietary Supplement
Lead sponsor
Oregon Health and Science University
Other
Eligibility
6 Years to 12 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
Columbus, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 2 Interventional

Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease

NCT00624351
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Epratuzumab, Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)

NCT02706951
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, Upadacitinib, Placebo Upadacitinib, Placebo Methotrexate
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
52
States / cities
Huntsville, Alabama • Mobile, Alabama • Gilbert, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Not applicable Interventional

Ankle Exoskeleton for Stroke Gait Enhancement

NCT07179627
View directory record Official record
Conditions
Stroke
Interventions
Ankle exoskeleton, Baseline (no ankle exoskeleton)
Device · Other
Lead sponsor
Georgia Institute of Technology
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Not applicable Interventional

Resistance Training During Maintenance Dialysis

NCT00363961
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Resistance exercise
Behavioral
Lead sponsor
Tufts University
Other
Eligibility
30 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 2 Interventional

Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF

NCT05284617
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
HU6, Placebo
Drug
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
40 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Beverly Hills, California • Torrance, California • Hialeah, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 29, 2026, 2:30 PM EDT
Recruiting Not applicable Interventional

Home Neuromodulation for Neurogenic Bladder Management in Spinal Cord Injury

NCT07264868
View directory record Official record
Conditions
Spinal Cord Injury (SCI), Neurogenic Bladder (NB)
Interventions
iTNS, Sham iTNS
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 3 Interventional

Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis

NCT00364091
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
R89674 0.025% ophthalmic solution
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
6
States / cities
Louisville, Kentucky • North Andover, Massachusetts • Creve Coeur, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 29, 2026, 2:30 PM EDT
Not listed Phase 2 Interventional

Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH

NCT04702490
View directory record Official record
Conditions
NASH, NASH - Nonalcoholic Steatohepatitis, Type 2 Diabetes, Diabetes Type 2, Diabetes, Fatty Liver, Fatty Liver, Nonalcoholic, NAFLD
Interventions
MET409 Active, MET409 Placebo, Empagliflozin
Drug
Lead sponsor
Metacrine, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Fort Myers, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 29, 2026, 2:30 PM EDT